Maintaining stable symptom control in inflammatory bowel disease: A retrospective analysis of adherence, medication switches and the risk of relapse

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 5, 2013, Pages 531-538

  Robinson, A ^a   Hankins, M ^b   Wiseman, G ^c   Jones, M ^d  

^a SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c Warner Chilcott UK Ltd   (United Kingdom)

^d Sciensus Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; MESREN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG FORMULATION; ENTERITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION THERAPY MANAGEMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; RISK FACTOR; SYMPTOM; TREATMENT DURATION; ULCERATIVE COLITIS; UNITED KINGDOM;

EID: 84882453119     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12396     Document Type: Article

References (16)

1. Dignass A, Lindsay JO, Sturm A, et al,. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: current management. J Crohns Colitis 2012; 6: 991-1030.
2. Mowat C, Cole A, Windsor A, et al,. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60: 571-607.
3. Feagan BG, Macdonald JK,. Oral 5-Aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 10: CD000544.
4. Kane SV,. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 577-85.
5. Shale MJ, Riley SA,. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 191-8.
6. Kane S, Huo D, Aikens J, Hanauer S,. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 39-43.
7. Khan N, Abbas AM, Bazzano LA, Koleva YN, Krousel-Wood M,. Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system. Aliment Pharmacol Ther 2012; 36: 755-64.
8. Forbes A, Cartwright A, Marchant S, McIntyre P, Newton M,. Review article: oral, modified-release mesalazine formulations-proprietary versus generic. Aliment Pharmacol Ther 2003; 17: 1207-14.
9. Healey CJ, O'Malley J,. Pharmacy-led switches of 5-ASA: impact on secondary care. Frontline Gastroenterol 2013; 4: 88-90.
10. Peterson AM, Nau DP, Cramer JA, et al,. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007; 10: 3-12.
11. Halpern MT, Khan ZM, Schmier JK, et al,. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension 2006; 47: 1039-48.
12. Yen L, Wu J, Hodgkins PL, Cohen RD, Nichol MB,. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-Aminosalicylic Acid therapy. J Manag Care Pharm 2012; 18: 701-12.
13. Jackson CA, Clatworthy J, Robinson A, Horne R,. Factors associated with non-Adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol 2010; 105: 525-39.
14. NHS Dumfries and Galloway. Mesalazine MR 400 mg Switch Project Protocol. 2012. Available at: http://www.dgprescribingmatters.co.uk/documents/ Mesalazine%20drug%20choice%20review.pdf. Accessed May 2013.
15. Bodalia P, Honey L,. Introducing Octasa MR (mesalazine)-The lowest cost, oral, pH-dependent modified-release mesalazine formulation available? B J Clin Pharm 2013; Feb: 1-4.
16. Black N, Barker M, Payne M,. Cross sectional survey of multicentre clinical databases in the United Kingdom. BMJ 2004; 328: 1478.